The relationship between chronic kidney disease (CKD) and upper tract urothelial carcinomas (UTUC) is an important and highlighted issue. UTUC patients could develop CKD. CKD, especially in renal transplant recipients, is associated with higher incidence of UTUC. Aristolochic acid (AA) has been recognized as a risk factor of CKD and a strong carcinogen for urothelial carcinomas. There has been much progress in diagnosis, treatment, and prognostic factors of UTUC recently. Computed tomography urography (CTU) has become an effective diagnostic tool for UTUC. The identification of aristolactam-DNA adducts in UTUC patients clarifies the presence of AA exposure. Nephron-sparing surgeries serve as an alternative in low-risk UTUC patients and spare the sequelae of CKD with standard nephroureterectomy. Tumor stage and lymphovascular invasion status are important predictors of survival in UTUC patients. Nonetheless, little is known and challenges remain about the feasibility and results of these new diagnostic and treatment techniques and survival predictors in UTUC patients having CKD. To provide a better care for these patients, understanding their risk factors, natural history, diagnosis, therapy, and outcomes may aid the development of effective strategies. We invite authors to submit original research and review articles that are related to UTUC in CKD patients, regarding new advances in diagnosis, treatment, and algorithms as well as risk factors, ethnicity, genetics, and societal impact. Potential topics include, but are not limited to:

• New diagnostic tool for UTUC in CKD patients
• The influence and outcomes of CKD in UTUC treatments
• Recent advances in endourological treatments of UTUC in CKD patients
• The role of gender, ethnicity, exposures, and genetics of UTUC in CKD patients
• Mechanisms of developing UTUC in CKD patients
• Role of inflammation and immunity of UTUC in CKD patients
• The algorithms of renal function monitoring and recurrence detection
• Societal perspectives, economic impacts, and qualities of life

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/nephrology/kipu/ according to the following timetable: